The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy

Cancer

Volumn 122, Issue 8, 2016, Pages 1160-1168

  Falchi, Lorenzo ^a   Verstovsek, Srdan ^a   Ravandi Kashani, Farhad ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute promyelocytic leukemia; all trans retinoic acid; arsenic trioxide; oral arsenic

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGRESSION; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEART ARRHYTHMIA; HEART DEATH; HUMAN; LEUKOCYTOSIS; LIVER TOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AMBULATORY CARE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; FORECASTING; HEMATOLOGIC NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; OXIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84952837775     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29852     Document Type: Review

References (63)

1. Doyle AC,. Notes of a case of leukocythaemia. Lancet. 1882; 119: 490.
2. Zhang P, Wang S, Hu L, et al., Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases [article in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2000; 21: 67-70.
3. Chen GQ, Zhu J, Shi XG, et al., In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88: 1052-1061.
4. de The H, Chomienne C, Lanotte M, Degos L, Dejean A,. The t(15;17) translocation in acute promyelocytic laeukemia fuses the retinoic acid receptor α gene to another transcribed locus. Nature. 1990; 347: 558-561.
5. Daniel MT, Koken M, Romagne O, et al., PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood. 1993; 82: 1858-1867.
6. Grignani F, De Matteis S, Nervi C, et al., Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998; 391: 815-818.
7. Duprez E, Wagner K, Koch H, Tenen DG,. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 2003; 22: 5806-5816.
8. Roboz GJ, Dias S, Lam G, et al., Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000; 96: 1525-1530.
9. Shen Z, Chen G, Ni J, et al., Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 3354-3360.
10. Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV,. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest. 2001; 108: 1541-1547.
11. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al., Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999; 189: 1043-1052.
12. Fujisawa S, Ohno R, Shigeno K, et al., Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol. 2007; 59: 485-493.
13. Zhou J, Meng R, Sui X, Meng L, Jia J, Yang B,. Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis. Haematologica. 2005; 90: 1277-1279.
14. Kumana CR, Au WY, Lee NS, et al., Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol. 2002; 58: 521-526.
15. Lu D, Qiu J, Jiang B, et al., Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002; 99: 3136-3143.
16. Sweeney CJ, Takimoto C, Wood L, et al., A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010; 66: 345-356.
17. Au WY, Kwong YL,. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin. 2008; 29: 296-304.
18. Lengfelder E, Hofmann WK, Nowak D,. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012; 26: 433-442.
19. Douer D, Hu W, Giralt S, Lill M, DiPersio J,. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist. 2003; 8: 132-140.
20. Thirugnanam R, George B, Chendamarai E, et al., Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009; 15: 1479-1484.
21. Lou Y, Suo S, Tong Y, et al., Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy. Ann Hematol. 2014; 93: 941-948.
22. Specchia G, Lo Coco F, Vignetti M, et al., Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol. 2001; 19: 4023-4028.
23. Tsimberidou AM, Estey E, Whitman GJ, et al., Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res. 2004; 28: 991-994.
24. Lengfelder E, Lo-Coco F, Ades L, et al., Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia. 2015; 29: 1084-1091.
25. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al., Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006; 17: 131-134.
26. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al., Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011; 29: 2753-2757.
27. Mathews V, George B, Lakshmi KM, et al., Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107: 2627-2632.
28. Mathews V, George B, Chendamarai E, et al., Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28: 3866-3871.
29. Zhang Y, Zhang Z, Li J, et al., Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013; 119: 115-125.
30. Powell BL, Moser B, Stock W, et al., Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116: 3751-3757.
31. Gore SD, Gojo I, Sekeres MA, et al., Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010 20; 28: 1047-1053.
32. Huang BT, Zeng QC, Gurung A, Zhao WH, Xiao Z, Li BS,. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Med Oncol. 2012; 29: 2088-2094.
33. Huang H, Qin Y, Xu R, et al., Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leuk Res. 2012; 36: 841-845.
34. Song X, Hu X, Lu S, et al., Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Eur J Haematol. 2014; 93: 54-62.
35. Iland HJ, Collins M, Bradstock K, et al., Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial [serial online]. Lancet Haematol. 2015; 2: e357-e366.
36. Estey E, Garcia-Manero G, Ferrajoli A, et al., Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006; 107: 3469-3473.
37. Ravandi F, Estey E, Jones D, et al., Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009; 27: 504-510.
38. Shen ZX, Shi ZZ, Fang J, et al., All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101: 5328-5335.
39. Hu J, Liu YF, Wu CF, et al., Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106: 3342-3347.
40. Lou Y, Qian W, Meng H, et al., High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res. 2013; 37: 37-42.
41. Dai CW, Zhang GS, Shen JK, et al., Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 2009; 121: 1-8.
42. Lo-Coco F, Avvisati G, Vignetti M, et al., Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369: 111-121.
43. Roboz GJ, Ritchie EK, Curcio T, et al., Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer. 2008; 113: 2504-2511.
44. Aldoss I, Mark L, Vrona J, et al., Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia. Ann Hematol. 2014; 93: 1839-1843.
45. Welch JS, Klco JM, Gao F, et al., Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011; 86: 796-800.
46. Martelli MP, Gionfriddo I, Mezzasoma F, et al., Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015; 125: 3455-3465.
47. El Hajj H, Dassouki Z, Berthier C, et al., Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood. 2015; 125: 3447-3454.
48. Verstovsek S, Giles F, Quintas-Cardama A, et al., Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol. 2006; 24: 181-188.
49. Schiller GJ, Slack J, Hainsworth JD, et al., Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006; 24: 2456-2464.
50. Vey N, Bosly A, Guerci A, et al., Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006; 24: 2465-2471.
51. Wei W, Zhou F, Zhang Y, Guo L, Shi H, Hou J,. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes. Leuk Res. 2012; 36: 715-719.
52. Sekeres MA, Maciejewski JP, Erba HP, et al., A phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer. 2011; 117: 1253-1261.
53. Roboz GJ, Ritchie EK, Curcio T, et al., Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leuk Res. 2011; 35: 522-525.
54. Bejanyan N, Tiu RV, Raza A, et al., A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 2012; 118: 3968-3976.
55. Au W, Kumana CR, Kou M, et al., Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood. 2003; 102: 407-408.
56. Au WY, Kumana CR, Lee HK, et al., Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011; 118: 6535-6543.
57. Firkin F,. Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study. Intern Med J. 2012; 42: 948-952.
58. Zhu HH, Wu DP, Jin J, et al., Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013; 31: 4215-4221.
59. Zhu H, Huang XJ,. Oral arsenic and retinoic acid for nonhigh-risk acute promyelocytic leukemia. N Engl J Med. 2014; 371: 2239-2241.
60. Au WY, Cheung GT, Yuen TW, Kumana CR, Kwong YL,. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med. 2005; 165: 1067-1068.
61. Au WY, Fong BM, Tam S, Kwong YL,. Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis. Ann Hematol. 2013; 92: 417-418.
62. Au WY, Liu CL, Tam S, et al., Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure. Ann Hematol. 2007; 86: 771-772.
63. Lo Coco F, Cicconi L,. Outpatient oral treatment for acute promyelocytic leukemia. N Engl J Med. 2015; 372: 884-885.